Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07084896 · ClinicalTrials.gov registry record · Phase 1

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

A Phase 1 study of Multiple Myeloma, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 1
Development phase
106
Enrollment target
20
Study locations

NCT07084896 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 106 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07084896, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
106 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Belantamab mafodotin
  • DRUG Nirogacestat

Study Locations (20)

Other

  • GSK Investigational Site - Lille
  • GSK Investigational Site - Villejuif
  • GSK Investigational Site - Frankfurt
  • GSK Investigational Site - Kiel
  • GSK Investigational Site - Leipzig
  • GSK Investigational Site - Athens
  • GSK Investigational Site - Utrecht
  • GSK Investigational Site - Oslo
  • GSK Investigational Site - Katowice
  • GSK Investigational Site - Lodz
  • GSK Investigational Site - Lublin
  • GSK Investigational Site - Moscow
  • GSK Investigational Site - Incheon

Georgia

  • 238995 - Atlanta

Massachusetts

  • 240593 - Boston

Michigan

  • 251164 - Grand Rapids

Wisconsin

  • 239015 - Madison

Victoria

  • GSK Investigational Site - Fitzroy

British Columbia

  • GSK Investigational Site - Vancouver

Nova Scotia

  • GSK Investigational Site - Halifax

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2020-06-08
Est. Completion 2027-03-11
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07084896

The ClinicalTrials.gov registry entry for NCT07084896 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Belantamab mafodotin is the first listed.

NCT07084896 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Georgia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07084896 about?

NCT07084896 is a clinical study titled "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM". The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the M...

What is the current status of trial NCT07084896?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2020-06-08. Estimated completion is 2027-03-11.

What conditions does trial NCT07084896 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT07084896?

The interventions under investigation include: Belantamab mafodotin (DRUG), Nirogacestat (DRUG).

Who is sponsoring clinical trial NCT07084896?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07084896 being conducted?

This trial has 20 study locations across Georgia, Massachusetts, Michigan, Wisconsin, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.